How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,042 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database. (Abstract)

≥0 were extracted. The median age at DIL onset was 49 years and the female to male sex ratio was 4.3. The median delay between start of suspected treatment and DIL occurrence was 172 days. DIL was reported as serious adverse event in 55.4%. Among the 118 suspected drugs, 42 had not been previously reported in association with DIL. The drugs associated with the highest number of DIL cases were infliximab, adalimumab, etanercept, procainamide and hydralazine.This study enables the identification

2019 Annals of the Rheumatic Diseases

105. Idiopathic Ventricular Tachycardias for the EM Physician

regular tachycardia according to our ACC/AHA guidelines as an option, assuming you do not think it's SVT. I would say in general that, if you do not suspect a particular SVT with aberrancy or a particular idiopathic VT on the differential, then just revert back to your classic strategy for wide complex regular tachycardia. For many people, this includes drugs like amiodarone or procainamide (if you can get it easily), all vs. elective cardioversion. Remember, these idiopathic VTs are really only (...) procainamide. For SVT with aberrancy, amiodarone does have AV nodal blocking effects, so that may break and suppress the rhythm. For IVT, I do not know which particular rhythms would respond to amiodarone (I don't think anyone knows this), but I could imagine that sometimes it may work. Just as long as the rhythm is not irregular and polymorphic (like AF with WPW would be) then I don't see any clear downside to amiodarone, except that it might simply not work in many scenarios. Subscribe to: Recommended

2018 Dr Smith's ECG Blog

106. A Middle-Aged Man with Chest pain, Hypotension and Tachycardia

records. We did know he was on a beta blocker, so it could have been the case that he is in chronic atrial fib/flutter. However, he was in shock and we had to take the risk of cardioversion. 3. Chemical cardioversion. Without first giving an AV nodal blocker, chemical cardioversion with agents such as procainamide can paradoxically increase the ventricular rate by slowing the atrial flutter rate enough for the AV node to conduct every beat; 1:1 conduction would result in a much faster ventricular rate

2018 Dr Smith's ECG Blog

110. Management of Supraventricular Tachycardia of Children

at some point. While in most cases ventricular tachycardia can be considered a benign rhythm disorder, special consideration needs to be given to infants, athletes and patients with Wolff-Parkinson-White syndrome. Condition or disease Intervention/treatment Supraventricular Tachycardia Drug: adenosine,Propranolol,flecainide, amiodarone, propranolol, digoxin and procainamide. Study Design Go to Layout table for study information Study Type : Observational [Patient Registry] Estimated Enrollment : 50 (...) and Cohorts Go to Intervention Details: Drug: adenosine,Propranolol,flecainide, amiodarone, propranolol, digoxin and procainamide. drugs used for treatment of supraventricular tachycardia Outcome Measures Go to Primary Outcome Measures : Evaluate management of SVT in the cardiology unit of Assiut University Children Hospital according to international guidelines by using pharmacological and non pharmacological treatments. [ Time Frame: one year ] Descriptive sheet of the study checklist that will be asked

2018 Clinical Trials

111. BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

. These include but are not limited to Class I antiarrhythmics (eg, quinidine, procainamide, dysopiramide, lidocaine, phenytoin, mexiletine, tocainide, flecainide, propafenone, moricizine), Grapefruit and Seville oranges. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its identifier (NCT

2018 Clinical Trials

112. Fluoxetine Opens Window to Improve Motor Recovery After Stroke

, congestive heart failure) Resting blood pressure exceeding 180/100mmHg Requires more than a one person assist for transfer Planned surgery that would affect participation in the trial Participating in another formal lower limbs exercise program more than one day per week History of QT prolongation or concomitant use of clearly identified potential QT prolonging drugs, at the investigators discretion (e.g. amiodarone, bepridil, dysopyramide, dofetilide, flecainide, ibutilide, procainamide, propafenone

2018 Clinical Trials

113. Memantine and Post-mastectomy Neuropathic Pain

, Patient with drug treatments evaluated by the investigator to be not compatible with the trial, Patient treated with specific drugs (amantadine, ketamine, dextromethorphan, L-Dopa, dopaminergic, anticholinergic agonists, barbituric, neuroleptic, IMAO, antispastic agents, dantrolen or baclofen, phenytoin, cimetidine, ranitidine, procainamide, quinidine, quinine, nicotine, hydrochlorothiazide, warfarine), Patient with alcohol addiction, Epileptic patient or history of epileptic seizure or convulsions

2018 Clinical Trials

114. Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer

drug within 30 days prior to first dose of panitumumab-IRDye800. Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment. Previous bilateral neck dissection. History of infusion reactions to monoclonal antibody therapies. Pregnant or breastfeeding. Magnesium or potassium lower than the normal institutional values. Subjects receiving class IA (quinidine, procainamide

2018 Clinical Trials

115. Cohort of Patients Referred for Brugada Syndrome Investigation in an Electrophysiology Service - 19-Year Registry Full Text available with Trip Pro

-three patients (65.7%) were asymptomatic, 6 (17.14%) had palpitations, 5 (14.3%) had syncope, and 3 (8.6%) had a family history of sudden death. Electrophysiological study induced ventricular tachyarrhythmias in 16 cases (45.7%), the mean ventricular refractory period being 228 ± 36 ms. Ajmaline / procainamide was used in 11 cases (31.4%), changing the ECG pattern to type I in 7 (63.6%). Sixteen cases (45.7%) received an implantable cardioverter defibrillator (ICD). In a mean 5-year follow-up, 1

2018 Arquivos brasileiros de cardiologia

116. Marijuana Induced Type I Brugada Pattern: A Case Report Full Text available with Trip Pro

. We here present an interesting case of Type I Brugada pattern in electrocardiography (ECG) in a 36 year old healthy African American male who presented after smoking four joints. Urine toxicology test proved marijuana use. Acute coronary syndrome was ruled out, coronary angiogram revealed normal coronaries, 2D echocardiogram showed no evidence of structural heart disease. Upon resolution of Brugada pattern in ECG, procainamide challenge performed in electrophysiology laboratory did not induce

2018 American journal of medical case reports

117. Effect of Baseline Antiarrhythmic Drug on Outcomes With Ablation in Ischemic Ventricular Tachycardia: A VANISH Substudy (Ventricular Tachycardia Ablation Versus Escalated Antiarrhythmic Drug Therapy in Ischemic Heart Disease). Full Text available with Trip Pro

patient on procainamide rather than sotalol). Amio-refractory patients had more renal insufficiency (23.7% versus 10%; P=0.0008), worse New York Heart Association class (82.3% II/III versus 65.5%; P=0.0003), and lower ejection fraction (29±9.7% versus 35.2±11%; P<0.0001). Within the amio-refractory group, ablation resulted in reduction of any ventricular arrhythmia compared with escalated drug therapy (hazard ratio, 0.53; 95% confidence interval, 0.31-0.9), P=0.020). Sotalol-refractory patients had

2018 Circulation. Arrhythmia and electrophysiology Controlled trial quality: uncertain

118. Amiodarone for sustained stable ventricular tachycardia in the prehospital setting. (Abstract)

for cardioversion occurring very infrequently. Amiodarone was relatively safe and moderately effective for the treatment of sustained stable VT. However, given recent evidence of increased efficacy of procainamide for stable VT, further studies are required in the prehospital setting to compare these two drugs.© 2018 Australasian College for Emergency Medicine and Australasian Society for Emergency Medicine.

2018 Emergency medicine Australasia

119. Drug-induced lupus: Traditional and new concepts. (Abstract)

Drug-induced lupus: Traditional and new concepts. Drug-induced lupus (DIL) includes a spectrum of drug-induced reactions often characterised by a clinical phenotype similar to that of idiopathic systemic lupus eruthematosus (SLE) but usually lacking major SLE complications. Different drugs may be associated with distinct clinical and serological profiles, and early recognition is crucial. Drugs traditionally associated with DIL include procainamide, hydralazine, quinidine and others, but strong

2018 Autoimmunity reviews

120. Pilot Randomized Trial With Flecainide in ARVC Patients

contraindication to beta-blockers exists. Persons prescribed quinidine, procainamide, propafenone, disopyramide, dronedarone phenytoin, mexilitene, flecainide, may be included after 5 day washout period with subsequent 24 Hour Holter obtained after washout period. Persons prescribed sotalol must be included after 5 day washout period during which another beta-blocker may be administered with subsequent 24 Hour Holter obtained. Subject and personal physician and or cardiologist must agree not to use any

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>